elacestrant

Term ID

CHEBI:229213

Synonyms

(6R)-6-[2-(ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
elacestrant
elacestrantum
ER-306323
Orserdu
RAD 1901
RAD-1901
RAD1901

Definition

A member of the class of tetralins that is 1,2,3,4-tetrahydronaphthalene which is substituted by hydroxy group at position 2 and by a 2-(ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl group at position 6R. It is a is an estrogen receptor degrader indicated for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

References

cas:722533-56-4
drugbank:DB06374
kegg.drug:D11671
pdb-ccd:I0V
pmc:PMC10554897
pubmed:28473534
pubmed:31426673
pubmed:31852484
pubmed:32912274
pubmed:33513026
pubmed:33589422
pubmed:34798371
pubmed:35348779
pubmed:35584336
pubmed:35621343
pubmed:35737918
pubmed:36446866
pubmed:36813113
pubmed:36877283
pubmed:36960661
pubmed:36993871
pubmed:37060385
pubmed:37143269
pubmed:37191763
pubmed:37314500
pubmed:37318638
pubmed:37364222
pubmed:37485921
pubmed:37580832
pubmed:37594177
pubmed:37888769
pubmed:38006464
pubmed:38039056
pubmed:38169749
pubmed:38381994
wikipedia.en:Elacestrant

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from elacestrant

Phenotype where environments contain elacestrant

Phenotype modified by environments containing elacestrant

Phenotype affecting elacestrant

Human Disease Model